Logo image of TXMD

THERAPEUTICSMD INC (TXMD) Stock Fundamental Analysis

NASDAQ:TXMD - Nasdaq - US88338N2062 - Common Stock - Currency: USD

1.01  -0.01 (-0.98%)

Fundamental Rating

4

TXMD gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. TXMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TXMD has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TXMD had negative earnings in the past year.
TXMD had a negative operating cash flow in the past year.
In the past 5 years TXMD reported 4 times negative net income.
In the past 5 years TXMD always reported negative operating cash flow.
TXMD Yearly Net Income VS EBIT VS OCF VS FCFTXMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -8.38%, TXMD is in the better half of the industry, outperforming 71.89% of the companies in the same industry.
Looking at the Return On Equity, with a value of -12.24%, TXMD is in the better half of the industry, outperforming 75.68% of the companies in the same industry.
Industry RankSector Rank
ROA -8.38%
ROE -12.24%
ROIC N/A
ROA(3y)-0.57%
ROA(5y)-33.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TXMD Yearly ROA, ROE, ROICTXMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

TXMD has a Gross Margin of 81.58%. This is amongst the best in the industry. TXMD outperforms 87.03% of its industry peers.
In the last couple of years the Gross Margin of TXMD has grown nicely.
The Profit Margin and Operating Margin are not available for TXMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.88%
GM growth 5Y3.8%
TXMD Yearly Profit, Operating, Gross MarginsTXMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

More info and screens

6

2. Health

2.1 Basic Checks

TXMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TXMD has been increased compared to 1 year ago.
TXMD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for TXMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TXMD Yearly Shares OutstandingTXMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
TXMD Yearly Total Debt VS Total AssetsTXMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

TXMD has an Altman-Z score of -33.31. This is a bad value and indicates that TXMD is not financially healthy and even has some risk of bankruptcy.
TXMD has a worse Altman-Z score (-33.31) than 91.35% of its industry peers.
There is no outstanding debt for TXMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -33.31
ROIC/WACCN/A
WACC9.88%
TXMD Yearly LT Debt VS Equity VS FCFTXMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 2.03 indicates that TXMD has no problem at all paying its short term obligations.
With a Current ratio value of 2.03, TXMD perfoms like the industry average, outperforming 40.54% of the companies in the same industry.
A Quick Ratio of 2.03 indicates that TXMD has no problem at all paying its short term obligations.
TXMD has a Quick ratio of 2.03. This is comparable to the rest of the industry: TXMD outperforms 45.41% of its industry peers.
Industry RankSector Rank
Current Ratio 2.03
Quick Ratio 2.03
TXMD Yearly Current Assets VS Current LiabilitesTXMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for TXMD have decreased strongly by -103.85% in the last year.
TXMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -18.57%.
TXMD shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -39.53% yearly.
EPS 1Y (TTM)-103.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.14%
Revenue 1Y (TTM)-18.57%
Revenue growth 3Y-72.82%
Revenue growth 5Y-39.53%
Sales Q2Q%1194%

3.2 Future

The Earnings Per Share is expected to grow by 20.36% on average over the next years. This is a very strong growth
TXMD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.13% yearly.
EPS Next Y192.11%
EPS Next 2Y70.91%
EPS Next 3Y34.76%
EPS Next 5Y20.36%
Revenue Next Year350%
Revenue Next 2Y113.31%
Revenue Next 3Y66.91%
Revenue Next 5Y37.14%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TXMD Yearly Revenue VS EstimatesTXMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
TXMD Yearly EPS VS EstimatesTXMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 -10 -20 -30

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TXMD. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 2.83, the valuation of TXMD can be described as very cheap.
Based on the Price/Forward Earnings ratio, TXMD is valued cheaply inside the industry as 98.38% of the companies are valued more expensively.
TXMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 2.83
TXMD Price Earnings VS Forward Price EarningsTXMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TXMD Per share dataTXMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

TXMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TXMD's earnings are expected to grow with 34.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y70.91%
EPS Next 3Y34.76%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TXMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERAPEUTICSMD INC

NASDAQ:TXMD (2/20/2025, 8:00:01 PM)

1.01

-0.01 (-0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-20 2025-02-20/amc
Earnings (Next)05-08 2025-05-08
Inst Owners29.64%
Inst Owner Change4.43%
Ins Owners1.77%
Ins Owner Change0.03%
Market Cap11.65M
Analysts43.33
Price TargetN/A
Short Float %1.53%
Short Ratio0.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2.83
P/S 7.3
P/FCF N/A
P/OCF N/A
P/B 0.43
P/tB 0.51
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)0.36
Fwd EY35.35%
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.14
BVpS2.35
TBVpS1.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.38%
ROE -12.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.58%
FCFM N/A
ROA(3y)-0.57%
ROA(5y)-33.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.88%
GM growth 5Y3.8%
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.03
Quick Ratio 2.03
Altman-Z -33.31
F-Score3
WACC9.88%
ROIC/WACCN/A
Cap/Depr(3y)110.08%
Cap/Depr(5y)867.47%
Cap/Sales(3y)28.97%
Cap/Sales(5y)27.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-103.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.14%
EPS Next Y192.11%
EPS Next 2Y70.91%
EPS Next 3Y34.76%
EPS Next 5Y20.36%
Revenue 1Y (TTM)-18.57%
Revenue growth 3Y-72.82%
Revenue growth 5Y-39.53%
Sales Q2Q%1194%
Revenue Next Year350%
Revenue Next 2Y113.31%
Revenue Next 3Y66.91%
Revenue Next 5Y37.14%
EBIT growth 1Y-106.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-112.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-112.46%
OCF growth 3YN/A
OCF growth 5YN/A